Minnesota Insurers File Suit Against GlaxoSmithKline Over Delay of Generic Versions of Antidepressant Paxil

Main Category: Pharma Industry / Biotech Industry
Article Date: 15 May 2005 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated

.
Blue Cross and Blue Shield of Minnesota and 18 other health insurers in the state on Wednesday filed a lawsuit in U.S. District Court in Minneapolis alleging that GlaxoSmithKline "manipulated the federal patent system to keep cheaper generic alternatives" to the antidepressant Paxil from reaching the market, the Minneapolis Star Tribune reports. According to BCBSM, a generic version of Paxil could have reached the market as early as 1998. However, the lawsuit alleges that GSK maintained its monopoly on the drug by claiming to hold patents on scientific procedures used to make Paxil that already were in the public domain. In addition, GSK allegedly listed invalid patents with FDA that kept other pharmaceutical companies from bringing generic equivalents of Paxil to the market, the suit says. As a result, according to the insurers, a generic version for Paxil did not reach the market until late 2003, with a month's supply selling for $63. Paxil cost $93 per month at the time, according to BCBSM. The lawsuit says GSK violated federal and state antitrust and fraud laws and engaged in deceptive trade practices, according to the Star Tribune. In addition, the lawsuit alleges that GSK "harassed" generic drug manufacturers by filing frivolous lawsuits to prevent them from marketing their versions of Paxil and invoked a federal law granting GSK a 30-month extension on its Paxil patents. BCBSM and the other insurers -- which are being represented by Minneapolis law firm Robins, Kaplan, Miller and Ciresi -- are seeking unspecified financial damages. According to BCBSM senior counsel Tom Gilde, each insurer will review its claims data to determine the amount of financial damages they will seek from GSK. Nancy Pekarek, a spokesperson for GSK, said the company had not yet seen the lawsuit and could not comment on the allegations (Phelps, Minneapolis Star Tribune, 5/12).

"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Paxil CR.


Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Sarah Mandelson. "Minnesota Insurers File Suit Against GlaxoSmithKline Over Delay of Generic Versions of Antidepressant Paxil." Medical News Today. MediLexicon, Intl., 15 May. 2005. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/24304.php>

APA
Sarah Mandelson. (2005, May 15). "Minnesota Insurers File Suit Against GlaxoSmithKline Over Delay of Generic Versions of Antidepressant Paxil." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/24304.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »